Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5Gynecologic 5Thoracic 4Gastrointestinal 3CNS 3Tumor-Agnostic 2Sarcoma 2Head & Neck 2Breast 2Other hematologic neoplasm 1Myeloid 1

Conditions

Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Vaginal Neoplasms 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Endometrioid 1Brenner Tumor 1

Interventions

Paclitaxel 153Carboplatin 123Bevacizumab 87Cisplatin 66pembrolizumab 58Taxes 51Gemcitabine 51liposomal doxorubicin 39Topotecan 37olaparib 31Immunoglobulin G 27Disulfides 26Cyclophosphamide 24Brachytherapy 22Docetaxel 21human papillomavirus vaccine, L1 type 16, 18 20niraparib 19Platinum 19Nivolumab 18Magnetic Resonance Spectroscopy 181,2-diaminocyclohexaneplatinum II citrate 18rucaparib 17durvalumab 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 16Doxorubicin 16Radiotherapy, Intensity-Modulated 14Radiation 13Albumin-Bound Paclitaxel 13fludarabine phosphate 12fludarabine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × adavosertib × Gynecologic × Clear all
NCT02101775 2026-04-13

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
124 enrolled 17 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT03345784 2024-02-20

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

National Cancer Institute (NCI)

Phase 1 Terminated
10 enrolled 15 charts
Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms, Carcinoma, Endometrioid

NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AstraZeneca

Phase 2 Completed
95 enrolled 61 charts
Gynecologic

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

NCT01357161 2023-09-21

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Merck Sharp & Dohme LLC

Phase 2 Completed
136 enrolled 15 charts
Gynecologic

Ovarian Neoplasms

NCT01076400 2023-09-18

MK-1775-008

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
7 enrolled 6 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡